SPARSENTAN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C32H40N4O5S
Molecular Weight	592.749
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(COCC)=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(C)=C5C

InChI

InChIKey=WRFHGDPIDHPWIQ-UHFFFAOYSA-N

InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800024221 | http://www.retrophin.com/content/pipeline/sparsentan.php | https://www.ncbi.nlm.nih.gov/pubmed/29142983

Sparsentan (RE-021; BMS-346567; PS433540; DARA-a) is a novel candidate in development by Retrophin for the treatment of focal segmental glomerulosclerosis (FSGS), a serious kidney disorder that often leads to end-stage renal disease (ESRD). Sparsentan is a first-in-class, orally active, dual-acting angiotensin receptor blocker (ARB) and highly selective endothelin Type A receptor antagonist. Sparsentan has been used in trials studying the treatment of focal segmental glomerulosclerosis. The FDA and European Commission have granted sparsentan orphan drug designation for FSGS. Retrophin also is advancing sparsentan for the treatment of immunoglobulin A nephropathy (IgAN) , or Berger’s disease, which also can lead to ESRD. Retrophin is examining the ability of sparsentan to slow the decline of kidney function in patients with FSGS and IgAN.

Originator

Approval Year

PubMed

Title	Date	PubMed
Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics.	2005 Jan 13	15634011
Designed multiple ligands. An emerging drug discovery paradigm.	2005 Oct 20	16220969
Focal segmental glomerulosclerosis.	2011 Dec 22	22187987

Sample Use Guides

In Vivo Use Guide

Primary focal segmental glomerulosclerosis (FSGS): oral sparsentan 200 mg, 400 mg, or 800 mg once daily

Route of Administration: Oral

In Vitro Use Guide

Sparsentan is a highly potent dual angiotensin II and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively.

Name

Type

Language

SPARSENTAN

Official Name

English

DARA

Common Name

English

RE-021

Code

English

FILSPARI

Brand Name

English

Sparsentan [WHO-DD]

Common Name

English

sparsentan [INN]

Common Name

English

(1,1'-BIPHENYL)-2-SULFONAMIDE, 4'-((2-BUTYL-4-OXO-1,3-DIAZASPIRO(4.4)NON-1-EN-3-YL)METHYL)-N-(4,5-DIMETHYL-3-ISOXAZOLYL)-2'-(ETHOXYMETHYL)-

Systematic Name

English

PS-433540

Code

English

SPARSENTAN [USAN]

Common Name

English

4'-((2-BUTYL-4-OXO-1,3-DIAZASPIRO(4.4)NON-1-EN-3-YL)METHYI)-N-(4,5- DIMETHYLISOXAZOL-3-YL)-2'-(ETHOXYMETHYL)BIPHENYL-2-SULFONAMIDE

Systematic Name

English

PS433540

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C66930